The compound you described, 2-(2-methoxyethyl)-9-methyl-N-[3-(4-methyl-1-piperidinyl)propyl]-1-oxo-4-pyrido[3,4-b]indolecarboxamide, is a complex organic molecule with a very specific chemical structure.
**Here's a breakdown:**
* **Chemical Name:** This name describes the molecule's structure in a very detailed way. It tells us about:
* **2-(2-methoxyethyl):** A substituent group attached to the main molecule at position 2. It contains a methoxy group (CH3O-) linked to an ethyl group (-CH2CH3).
* **9-methyl:** A methyl group (CH3-) attached to the molecule at position 9.
* **N-[3-(4-methyl-1-piperidinyl)propyl]:** This part describes a specific amine group (-NH-) attached to the molecule. The amine is bonded to a propyl chain (-CH2CH2CH3) which itself is attached to a 4-methyl-1-piperidinyl group (a cyclic amine with a methyl substituent).
* **1-oxo-4-pyrido[3,4-b]indolecarboxamide:** This part describes the core structure of the molecule. It's a pyrido[3,4-b]indole (a fused ring system) with a carbonyl group (C=O) at position 1, an amide group (CONH-) at position 4, and a carboxyl group (COOH) attached to position 4.
**Importance for Research:**
While the exact purpose of this specific compound isn't clear from its name alone, it's likely to be a candidate drug molecule or a research tool used in fields like:
* **Pharmacology:** This type of molecule often exhibits biological activity and is a potential candidate for developing drugs for various diseases. The complex structure and specific substituents are likely tailored to interact with specific receptors or enzymes in the body.
* **Medicinal Chemistry:** Researchers use such molecules to study structure-activity relationships. By modifying the structure, they can understand how different functional groups affect the compound's activity, leading to the design of more potent or selective drugs.
* **Biochemistry:** This compound might be used as a tool to investigate the mechanisms of various biological processes. Its interactions with biological systems can provide valuable insights into the workings of cells and organisms.
**To understand the specific importance of this compound, you would need more information:**
* **Research context:** What specific area of research is it used in? What are the target biological pathways or receptors?
* **Published studies:** Are there any scientific publications related to this compound? What are the results of those studies?
Without that additional information, it's difficult to say definitively why this specific compound is important. However, based on its structure and complexity, it's likely to play a role in some area of biomedical research.
ID Source | ID |
---|---|
PubMed CID | 3237701 |
CHEMBL ID | 1450949 |
CHEBI ID | 116605 |
Synonym |
---|
AKOS001802179 |
2-(2-methoxyethyl)-9-methyl-n-[3-(4-methylpiperidin-1-yl)propyl]-1-oxo-1h,2h,9h-pyrido[3,4-b]indole-4-carboxamide |
MLS000087496 , |
2-(2-methoxyethyl)-9-methyl-n-[3-(4-methylpiperidin-1-yl)propyl]-1-oxo-2,9-dihydro-1h-beta-carboline-4-carboxamide |
smr000023719 |
MLS000876638 |
HMS1622L16 |
2-(2-methoxyethyl)-9-methyl-n-[3-(4-methylpiperidin-1-yl)propyl]-1-oxopyrido[3,4-b]indole-4-carboxamide |
HMS2449M20 |
2-(2-methoxyethyl)-9-methyl-n-[3-(4-methyl-1-piperidinyl)propyl]-1-oxo-4-pyrido[3,4-b]indolecarboxamide |
1-keto-2-(2-methoxyethyl)-9-methyl-n-[3-(4-methylpiperidino)propyl]-beta-carboline-4-carboxamide |
cid_3237701 |
2-(2-methoxyethyl)-9-methyl-n-[3-(4-methylpiperidin-1-yl)propyl]-1-oxidanylidene-pyrido[3,4-b]indole-4-carboxamide |
bdbm38395 |
CHEMBL1450949 |
Q27200285 |
SR-01000122924-1 |
sr-01000122924 |
CHEBI:116605 |
cid 3237701 |
Class | Description |
---|---|
beta-carbolines | Any pyridoindole containing a beta-carboline skeleton and their hydrogenated derivatives |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.7943 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 32.4648 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 32.4648 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.1838 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 56.2341 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
ClpP | Bacillus subtilis | Potency | 31.6228 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
Smad3 | Homo sapiens (human) | Potency | 3.5481 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |